The recombinant mouse GRO-Gamma (CXCL3) protein is expressed with a polyhistidine (His) tag at the C-terminus, which facilitates its purification. The protein sequence includes amino acids from Ala28 to Ser100, resulting in a molecular weight of approximately 9.3 kDa . The His tag allows for easy purification using nickel affinity chromatography, which is a common method for isolating His-tagged proteins.
CXCL3 is involved in several key biological processes:
Migration and Invasion: CXCL3 plays a significant role in the migration and invasion of trophoblasts, which are cells forming the outer layer of a blastocyst and providing nutrients to the embryo. This function is crucial for the proper implantation and development of the placenta .
Proliferation and Tubule Formation: CXCL3 is also involved in the proliferation and tubule formation of trophoblasts. These processes are essential for the development of the placental vasculature, which supports fetal development .
Cancer Progression: CXCL3 and its receptor, CXCR2, are overexpressed in prostate cancer cells, prostate epithelial cells, and prostate cancer tissues. This overexpression is associated with the progression and metastasis of prostate cancer. CXCL3 regulates the expression of target genes related to malignancy progression through autocrine and paracrine pathways .
Adipogenesis: CXCL3 acts as a novel adipokine, facilitating adipogenesis (the formation of fat cells) in an autocrine and/or paracrine manner. It induces the expression of transcription factors such as C/EBPβ and C/EBPδ, which are critical for adipocyte differentiation .
Due to its involvement in various biological processes, CXCL3 has significant clinical implications:
Preeclampsia: CXCL3 is implicated in the pathogenesis of preeclampsia, a pregnancy complication characterized by high blood pressure and damage to other organ systems. Its role in trophoblast migration and invasion is particularly relevant to this condition .
Cancer Therapy: Given its role in cancer progression, CXCL3 is a potential target for cancer therapy. Inhibiting CXCL3 or its receptor, CXCR2, could potentially slow down or prevent the progression of certain cancers, such as prostate cancer .
The recombinant mouse GRO-Gamma (CXCL3) protein is typically supplied as a lyophilized powder, which ensures its stability during shipping and storage. When stored at -20°C to -80°C, the lyophilized protein is stable for up to 12 months. Once reconstituted, the protein solution can be stored at 4-8°C for 2-7 days or at -20°C for up to 3 months .